drugset
drugset / Trial / NCT03879811

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

NCT03879811 ↗

Phase 2 Withdrawn Memorial Sloan Kettering Cancer Center Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether temozolomide followed by nivolumab is an effective treatment for MMR-proficient colorectal cancer, while causing few or mild side effects.

Timeline

Start
2019-03-13
Primary completion
2021-03
Completion
2021-03

Outcome

Outcome not reported

Stopped (Enrollment): “No accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 480 mg Intravenous
Subject Temozolomide Small molecule 150 mg/m2 Oral

Indications

colorectal cancer